Overall unmet coordination needs | Unmet coordination needs in handovers between hospital and GP# | Unmet coordination needs in handovers between internal hospital departments## | Unmet coordination needs at handovers between hospitals### | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N (%) | OR (95% CI) | ORadja(95% CI) | N (%) | OR (95% CI) | ORadja(95% CI) | N (%) | OR (95% CI) | ORadja(95% CI) | N (%) | OR (95% CI) | ORadja(95% CI) | |
Demographic characteristics | ||||||||||||
Gender | ||||||||||||
Women | 19 (19%) | 1.00 | 1.00 | 17 (20%) | 1.00 | 1.00 | 8 (9%) | 1.00 | 1.00 | 14 (18%) | 1.00 | 1.00 |
Men | 5 (15%) | 0.74 (0.25; 2.18) | 1.10 (0.31; 3.93) | 4 (13%) | 0.63 (0.19; 2.06) | 0.88 (0.25; 3.09) | 2 (6%) | 0.74 (0.15; 3.69) | 2.53 (0.37; 17.47) | 5 (24%) | 1.45 (0.46; 4.62) | 1.85a(0.48; 7.07) |
Age | ||||||||||||
<60 years of age | 14 (36%) | 1.00 | 1.00 | 9 (29%) | 1.00 | 1.00 | 7 (19%) | 1.00 | 1.00 | 9 (29%) | 1.00 | 1.00 |
≥60 years of age | 10 (11%) | 0.22*(0.09; 0.55) | 0.26*(0.10; 0.70) | 12 (14%) | 0.40 (0.15; 1.06) | 0.44 (0.16; 1.25) | 3 (3%) | 0.16*(0.04; 0.65) | 0.14*(0.03; 0.68) | 10 (14%) | 0.41 (0.15; 1.15) | 0.46b(0.15; 1.37) |
Marital status | ||||||||||||
No Partner | 5 (18%) | 1.00 | 1.00 | 3 (12%) | 1.00 | 1.00 | 2 (7%) | 1.00 | 1.00 | 4 (18%) | 1.00 | 1.00 |
Partner | 19 (19%) | 1.05 (0.33; 3.13) | 1.06 (0.32; 3.50) | 18 (20%) | 1.81 (0.49; 6.71) | 2.05 (0.51; 8.16) | 8 (8%) | 1.12 (0.22; 5.59) | 1.52 (0.24; 9.55) | 15 (19%) | 1.07 (0.32; 3.63) | 0.91c(0.25; 3.28) |
Education | ||||||||||||
Not higher education | 7 (10%) | 1.00 | 1.00 | 8 (12%) | 1.00 | 1.00 | 1 (1%) | 1.00 | 1.00 | 7 (13%) | 1.00 | 1.00 |
Higher education | 16 (29%) | 3.06*(1.36; 9.52) | 3.41*(1.23; 9.44) | 13 (28%) | 2.91*(1.09; 7.73) | 2.82*(1.04; 7.63) | 9 (17%) | 13.02*(1.60; 106.25) | 14.22*(1.61; 125.79) | 11 (26%) | 2.31 (0.81; 6.59) | 2.47d(0.82; 7.37) |
Clinical characteristics | ||||||||||||
Comorbidity | ||||||||||||
No comorbidity | 10 (25%) | 1.00 | 1.00 | 6 (18%) | 1.00 | 1.00 | 5 (13%) | 1. 00 | 1.00 | 7 (21%) | 1.00 | 1.00 |
Yes comorbidity | 12 (14%) | 0.49 (0.19; 1.26) | 0.75 (0.26; 2.13) | 14 (18%) | 0.99 (0.35; 2.84) | 1.24 (0.41; 3.80) | 5 (6%) | 0.44 (0.12; 1.63) | 0.83 (0.19; 3.67) | 11 (17%) | 0.82 (0.28; 2.34) | 1.15c(0.35; 3.78) |
Treatment | ||||||||||||
Surgery | ||||||||||||
No surgery | 3 (9%) | 1.00 | 1.00 | 5 (16%) | 1.00 | 1.00 | 2 (6%) | 0.55 | 1.00 | 3 (14%) | 1.00 | 1.00 |
Surgery | 21 (22%) | 2.89 (0.80; 10.41) | 2.98 (0.35; 25.77) | 16 (19%) | 1.27 (0.42; 3.81) | 0.37 (0.05; 3.04) | 8 (9%) | 1.43 (0.29; 7.08) | 0.63 (0.04; 9.04) | 16 (21%) | 1.55 (0.41; 5.91) | 6.06c(0.33; 110.58) |
Radiation | ||||||||||||
No radiation | 9 (18%) | 1.00 | 1.00 | 6 (13%) | 1.00 | 1.00 | 4 (8%) | 1.00 | 1.00 | 7 (27%) | 1.00 | 1.00 |
Radiation | 15 (19%) | 1.09 (0.44; 2.73) | 1.26 (0.44; 3.56) | 15 (21%) | 1.74 (0.62; 4.88) | 1.80 (0.60; 5.42) | 6 (8%) | 0.96 (0.26; 3.58) | 1.14 (0.26; 5.01) | 12 (16%) | 0.53 (0.18; 1.55) | 0.57c(0.18; 1.82) |
Chemotherapy | ||||||||||||
No chemotherapy | 8 (13%) | 1.00 | 1.00 | 7 (12%) | 1.00 | 1.00 | 4 (7%) | 1.00 | 1.00 | 10 (23%) | 1.00 | 1.00 |
Chemotherapy | 16 (24%) | 2.08 (0.82; 5.27) | 1.10 (0.30; 4.06) | 14 (24%) | 2.22 (0.82; 6.00) | 1.91 (0.49; 7.44) | 6 (9%) | 1.35 (0.36; 5.04) | 0.54 (0.07; 4.17) | 9 (16%) | 0.67 (0.24; 1.82) | 0.34c(0.08; 1.38) |
Hormones | ||||||||||||
No hormones | 9 (30%) | 1.00 | 1.00 | 9 (38%) | 1.00 | 1.00 | 2 (7%) | 1.00 | 1.00 | 5 (23%) | 1.00 | 1.00 |
Hormones | 15 (15%) | 0.41 (0.16; 1.07) | 0.45 (0.15; 1.33) | 12 (13%) | 0.25*(0.09; 0.70) | 0.21*(0.07; 0.66) | 8 (8%) | 1.24 (0.25; 6.20) | 1.39 (0.23; 8.55) | 14 (18%) | 0.75 (0.24; 2.39) | 0.87c(0.24; 3.11) |
Years since diagnosis | ||||||||||||
<3 years | 12 (20%) | 1.00 | 1.00 | 11 (22%) | 1.00 | 1.00 | 6 (10%) | 1.00 | 1.00 | 8 (17%) | 1.00 | 1.00 |
≥3 years | 12 (17%) | 0.83 (0.34; 2.01) | 0.99 (0.35; 2.78) | 10 (15%) | 0.66 (0.26; 1.71) | 0.61 (0.21; 1.76) | 4 (6%) | 0.56 (0.15; 2.10) | 0.73 (0.16; 3.38) | 11 (22%) | 1.38 (0.50; 3.38) | 1.98c(0.63; 6.25) |